Do analysts rate IBRX or MESO?

ImmunityBio presently has a consensus price target of $14.20, suggesting a potential upside of 97.77%. Given ImmunityBio's stronger consensus rating and higher possible upside, research analysts clearly believe ImmunityBio is more favorable than Mesoblast. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmunityBio 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71 Mesoblast 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33

Which has better valuation & earnings, IBRX or MESO?

Mesoblast has lower revenue, but higher earnings than ImmunityBio. Mesoblast is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ImmunityBio $113.29M 66.38 -$351.40M -$0.85 N/A Mesoblast $17.20M 109.29 -$102.14M -$0.54 N/A

Is IBRX or MESO more profitable?

Mesoblast has a net margin of 0.00% compared to ImmunityBio's net margin of -606.15%. Company Net Margins Return on Equity Return on Assets ImmunityBio -606.15% N/A -59.53% Mesoblast N/A N/A N/A

Does the media prefer IBRX or MESO?

In the previous week, ImmunityBio had 5 more articles in the media than Mesoblast. MarketBeat recorded 7 mentions for ImmunityBio and 2 mentions for Mesoblast. Mesoblast's average media sentiment score of 0.93 beat ImmunityBio's score of 0.45 indicating that Mesoblast is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Mesoblast 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer MESO or QGEN?

Qiagen has a consensus target price of $44.98, suggesting a potential upside of 23.41%. Given Qiagen's stronger consensus rating and higher probable upside, analysts clearly believe Qiagen is more favorable than Mesoblast. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mesoblast 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 Qiagen 1 Sell rating(s) 6 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.42

Which has better earnings & valuation, MESO or QGEN?

Qiagen has higher revenue and earnings than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mesoblast $17.20M 109.29 -$102.14M -$0.54 N/A Qiagen $2.09B 3.59 $424.88M $1.91 19.08

Is MESO or QGEN more profitable?

Qiagen has a net margin of 19.16% compared to Mesoblast's net margin of 0.00%. Qiagen's return on equity of 14.40% beat Mesoblast's return on equity. Company Net Margins Return on Equity Return on Assets Mesoblast N/A N/A N/A Qiagen 19.16% 14.40% 8.40%

Does the media refer more to MESO or QGEN?

In the previous week, Qiagen had 16 more articles in the media than Mesoblast. MarketBeat recorded 18 mentions for Qiagen and 2 mentions for Mesoblast. Mesoblast's average media sentiment score of 0.93 beat Qiagen's score of -0.43 indicating that Mesoblast is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mesoblast 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Qiagen 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer MESO or PCVX?

Vaxcyte has a consensus target price of $86.00, suggesting a potential upside of 83.25%. Given Vaxcyte's stronger consensus rating and higher possible upside, analysts plainly believe Vaxcyte is more favorable than Mesoblast. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mesoblast 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 Vaxcyte 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63

Which has better valuation and earnings, MESO or PCVX?

Mesoblast has higher revenue and earnings than Vaxcyte. Mesoblast is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mesoblast $17.20M 109.29 -$102.14M -$0.54 N/A Vaxcyte N/A N/A -$766.63M -$6.88 N/A

Is MESO or PCVX more profitable?

Mesoblast's return on equity of 0.00% beat Vaxcyte's return on equity. Company Net Margins Return on Equity Return on Assets Mesoblast N/A N/A N/A Vaxcyte N/A -32.51% -29.51%

Does the media favor MESO or PCVX?

In the previous week, Vaxcyte had 5 more articles in the media than Mesoblast. MarketBeat recorded 7 mentions for Vaxcyte and 2 mentions for Mesoblast. Mesoblast's average media sentiment score of 0.93 beat Vaxcyte's score of 0.31 indicating that Mesoblast is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mesoblast 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vaxcyte 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer MESO or IMVT?

Immunovant has a consensus target price of $37.33, indicating a potential upside of 19.85%. Given Immunovant's stronger consensus rating and higher possible upside, analysts plainly believe Immunovant is more favorable than Mesoblast. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mesoblast 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 Immunovant 1 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.45

Which has preferable valuation and earnings, MESO or IMVT?

Mesoblast has higher revenue and earnings than Immunovant. Mesoblast is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mesoblast $17.20M 109.29 -$102.14M -$0.54 N/A Immunovant N/A N/A -$505.61M -$2.78 N/A

Is MESO or IMVT more profitable?

Mesoblast's return on equity of 0.00% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets Mesoblast N/A N/A N/A Immunovant N/A -65.66% -59.88%

Does the media refer more to MESO or IMVT?

In the previous week, Immunovant had 6 more articles in the media than Mesoblast. MarketBeat recorded 8 mentions for Immunovant and 2 mentions for Mesoblast. Mesoblast's average media sentiment score of 0.93 beat Immunovant's score of 0.35 indicating that Mesoblast is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mesoblast 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunovant 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer MESO or LNTH?

Lantheus has a consensus target price of $101.86, indicating a potential upside of 1.60%. Given Lantheus' stronger consensus rating and higher possible upside, analysts clearly believe Lantheus is more favorable than Mesoblast. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mesoblast 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 Lantheus 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.73

Which has better valuation & earnings, MESO or LNTH?

Lantheus has higher revenue and earnings than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mesoblast $17.20M 109.29 -$102.14M -$0.54 N/A Lantheus $1.54B 4.23 $233.56M $4.15 24.16

Is MESO or LNTH more profitable?

Lantheus has a net margin of 18.05% compared to Mesoblast's net margin of 0.00%. Lantheus' return on equity of 29.32% beat Mesoblast's return on equity. Company Net Margins Return on Equity Return on Assets Mesoblast N/A N/A N/A Lantheus 18.05% 29.32% 15.00%

Does the media refer more to MESO or LNTH?

In the previous week, Lantheus had 3 more articles in the media than Mesoblast. MarketBeat recorded 5 mentions for Lantheus and 2 mentions for Mesoblast. Mesoblast's average media sentiment score of 0.93 beat Lantheus' score of 0.44 indicating that Mesoblast is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mesoblast 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Mesoblast (MESO) Competitors

$14.52 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$14.12 -0.40 (-2.72%)

As of 04:43 PM Eastern

Compare

MESO vs. IBRX, QGEN, PCVX, IMVT, and LNTH

Should you buy Mesoblast stock or one of its competitors? MarketBeat compares Mesoblast with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Mesoblast include ImmunityBio (IBRX), Qiagen (QGEN), Vaxcyte (PCVX), Immunovant (IMVT), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry.

How does Mesoblast compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and Mesoblast (NASDAQ:MESO) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

In the previous week, ImmunityBio had 5 more articles in the media than Mesoblast. MarketBeat recorded 7 mentions for ImmunityBio and 2 mentions for Mesoblast. Mesoblast's average media sentiment score of 0.93 beat ImmunityBio's score of 0.45 indicating that Mesoblast is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Mesoblast	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

8.6% of ImmunityBio shares are owned by institutional investors. Comparatively, 1.4% of Mesoblast shares are owned by institutional investors. 69.5% of ImmunityBio shares are owned by insiders. Comparatively, 18.8% of Mesoblast shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Mesoblast has a net margin of 0.00% compared to ImmunityBio's net margin of -606.15%.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-606.15%	N/A	-59.53%
Mesoblast	N/A	N/A	N/A

Mesoblast has lower revenue, but higher earnings than ImmunityBio. Mesoblast is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$113.29M	66.38	-$351.40M	-$0.85	N/A
Mesoblast	$17.20M	109.29	-$102.14M	-$0.54	N/A

ImmunityBio presently has a consensus price target of $14.20, suggesting a potential upside of 97.77%. Given ImmunityBio's stronger consensus rating and higher possible upside, research analysts clearly believe ImmunityBio is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Mesoblast	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

ImmunityBio has a beta of 0.03, suggesting that its stock price is 97% less volatile than the broader market. Comparatively, Mesoblast has a beta of 2.05, suggesting that its stock price is 105% more volatile than the broader market.

Summary

Mesoblast beats ImmunityBio on 8 of the 15 factors compared between the two stocks.

How does Mesoblast compare to Qiagen?

Mesoblast (NASDAQ:MESO) and Qiagen (NYSE:QGEN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability.

1.4% of Mesoblast shares are held by institutional investors. Comparatively, 70.0% of Qiagen shares are held by institutional investors. 18.8% of Mesoblast shares are held by company insiders. Comparatively, 9.0% of Qiagen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Mesoblast has a beta of 2.05, meaning that its share price is 105% more volatile than the broader market. Comparatively, Qiagen has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market.

In the previous week, Qiagen had 16 more articles in the media than Mesoblast. MarketBeat recorded 18 mentions for Qiagen and 2 mentions for Mesoblast. Mesoblast's average media sentiment score of 0.93 beat Qiagen's score of -0.43 indicating that Mesoblast is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mesoblast	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Qiagen	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Qiagen has a consensus target price of $44.98, suggesting a potential upside of 23.41%. Given Qiagen's stronger consensus rating and higher probable upside, analysts clearly believe Qiagen is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesoblast	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Qiagen	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.42

Qiagen has higher revenue and earnings than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesoblast	$17.20M	109.29	-$102.14M	-$0.54	N/A
Qiagen	$2.09B	3.59	$424.88M	$1.91	19.08

Qiagen has a net margin of 19.16% compared to Mesoblast's net margin of 0.00%. Qiagen's return on equity of 14.40% beat Mesoblast's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mesoblast	N/A	N/A	N/A
Qiagen	19.16%	14.40%	8.40%

Summary

Qiagen beats Mesoblast on 11 of the 15 factors compared between the two stocks.

How does Mesoblast compare to Vaxcyte?

Mesoblast (NASDAQ:MESO) and Vaxcyte (NASDAQ:PCVX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings.

Mesoblast has a beta of 2.05, suggesting that its share price is 105% more volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.24, suggesting that its share price is 24% more volatile than the broader market.

Vaxcyte has a consensus target price of $86.00, suggesting a potential upside of 83.25%. Given Vaxcyte's stronger consensus rating and higher possible upside, analysts plainly believe Vaxcyte is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesoblast	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

1.4% of Mesoblast shares are held by institutional investors. Comparatively, 96.8% of Vaxcyte shares are held by institutional investors. 18.8% of Mesoblast shares are held by insiders. Comparatively, 3.3% of Vaxcyte shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Vaxcyte had 5 more articles in the media than Mesoblast. MarketBeat recorded 7 mentions for Vaxcyte and 2 mentions for Mesoblast. Mesoblast's average media sentiment score of 0.93 beat Vaxcyte's score of 0.31 indicating that Mesoblast is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mesoblast	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vaxcyte	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Mesoblast's return on equity of 0.00% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mesoblast	N/A	N/A	N/A
Vaxcyte	N/A	-32.51%	-29.51%

Mesoblast has higher revenue and earnings than Vaxcyte. Mesoblast is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesoblast	$17.20M	109.29	-$102.14M	-$0.54	N/A
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A

Summary

Mesoblast beats Vaxcyte on 9 of the 14 factors compared between the two stocks.

How does Mesoblast compare to Immunovant?

Mesoblast (NASDAQ:MESO) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, valuation, earnings, institutional ownership and dividends.

1.4% of Mesoblast shares are owned by institutional investors. Comparatively, 47.1% of Immunovant shares are owned by institutional investors. 18.8% of Mesoblast shares are owned by insiders. Comparatively, 1.8% of Immunovant shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Mesoblast has a beta of 2.05, suggesting that its share price is 105% more volatile than the broader market. Comparatively, Immunovant has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market.

Immunovant has a consensus target price of $37.33, indicating a potential upside of 19.85%. Given Immunovant's stronger consensus rating and higher possible upside, analysts plainly believe Immunovant is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesoblast	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

In the previous week, Immunovant had 6 more articles in the media than Mesoblast. MarketBeat recorded 8 mentions for Immunovant and 2 mentions for Mesoblast. Mesoblast's average media sentiment score of 0.93 beat Immunovant's score of 0.35 indicating that Mesoblast is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mesoblast	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunovant	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Mesoblast has higher revenue and earnings than Immunovant. Mesoblast is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesoblast	$17.20M	109.29	-$102.14M	-$0.54	N/A
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A

Mesoblast's return on equity of 0.00% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mesoblast	N/A	N/A	N/A
Immunovant	N/A	-65.66%	-59.88%

Summary

Mesoblast beats Immunovant on 9 of the 14 factors compared between the two stocks.

How does Mesoblast compare to Lantheus?

Mesoblast (NASDAQ:MESO) and Lantheus (NASDAQ:LNTH) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, institutional ownership and earnings.

Mesoblast has a beta of 2.05, suggesting that its stock price is 105% more volatile than the broader market. Comparatively, Lantheus has a beta of -0.03, suggesting that its stock price is 103% less volatile than the broader market.

In the previous week, Lantheus had 3 more articles in the media than Mesoblast. MarketBeat recorded 5 mentions for Lantheus and 2 mentions for Mesoblast. Mesoblast's average media sentiment score of 0.93 beat Lantheus' score of 0.44 indicating that Mesoblast is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mesoblast	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantheus	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lantheus has a consensus target price of $101.86, indicating a potential upside of 1.60%. Given Lantheus' stronger consensus rating and higher possible upside, analysts clearly believe Lantheus is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesoblast	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

Lantheus has a net margin of 18.05% compared to Mesoblast's net margin of 0.00%. Lantheus' return on equity of 29.32% beat Mesoblast's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mesoblast	N/A	N/A	N/A
Lantheus	18.05%	29.32%	15.00%

Lantheus has higher revenue and earnings than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesoblast	$17.20M	109.29	-$102.14M	-$0.54	N/A
Lantheus	$1.54B	4.23	$233.56M	$4.15	24.16

1.4% of Mesoblast shares are owned by institutional investors. Comparatively, 99.1% of Lantheus shares are owned by institutional investors. 18.8% of Mesoblast shares are owned by insiders. Comparatively, 1.7% of Lantheus shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Lantheus beats Mesoblast on 11 of the 16 factors compared between the two stocks.

Get Mesoblast News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MESO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MESO vs. The Competition

Export

Metric	Mesoblast	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.88B	$3.28B	$6.45B	$12.42B
Dividend Yield	N/A	2.33%	2.69%	5.29%
P/E Ratio	N/A	17.93	22.30	24.19
Price / Sales	109.29	324.62	581.44	138.36
Price / Cash	N/A	116.27	42.31	57.88
Price / Book	3.11	6.63	9.84	6.72
Net Income	-$102.14M	$24.20M	$3.57B	$337.19M
7 Day Performance	-0.95%	-3.24%	-1.16%	0.48%
1 Month Performance	-7.75%	0.53%	3.85%	5.07%
1 Year Performance	37.63%	47.24%	27.40%	34.25%

Mesoblast Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MESO Mesoblast	1.2148 of 5 stars	$14.52 flat	N/A	+39.9%	$1.88B	$17.20M	N/A	80
IBRX ImmunityBio	2.4312 of 5 stars	$7.24 -3.7%	$14.20 +96.1%	+170.8%	$7.88B	$113.29M	N/A	590	Analyst Forecast
QGEN Qiagen	4.1509 of 5 stars	$36.16 -1.2%	$44.98 +24.4%	-24.4%	$7.54B	$2.10B	18.88	5,654
PCVX Vaxcyte	2.7419 of 5 stars	$48.91 -4.8%	$86.00 +75.8%	+35.4%	$7.42B	N/A	N/A	160	Insider Trade
IMVT Immunovant	2.3558 of 5 stars	$32.86 -1.3%	$37.33 +13.6%	+100.6%	$6.75B	N/A	N/A	120	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MESO) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mesoblast (MESO) Competitors

MESO vs. IBRX, QGEN, PCVX, IMVT, and LNTH

How does Mesoblast compare to ImmunityBio?

Summary

How does Mesoblast compare to Qiagen?

Summary

How does Mesoblast compare to Vaxcyte?

Summary

How does Mesoblast compare to Immunovant?

Summary

How does Mesoblast compare to Lantheus?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MESO vs. The Competition

Mesoblast Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mesoblast (MESO) Competitors

MESO vs. IBRX, QGEN, PCVX, IMVT, and LNTH

How does Mesoblast compare to ImmunityBio?

Does the media prefer IBRX or MESO?

Do institutionals and insiders hold more shares of IBRX or MESO?

Is IBRX or MESO more profitable?

Which has better valuation & earnings, IBRX or MESO?

Do analysts rate IBRX or MESO?

Which has more volatility & risk, IBRX or MESO?

Summary

How does Mesoblast compare to Qiagen?

Do institutionals & insiders hold more shares of MESO or QGEN?

Which has more risk & volatility, MESO or QGEN?

Does the media refer more to MESO or QGEN?

Do analysts prefer MESO or QGEN?

Which has better earnings & valuation, MESO or QGEN?

Is MESO or QGEN more profitable?

Summary

How does Mesoblast compare to Vaxcyte?

Which has more volatility and risk, MESO or PCVX?

Do analysts prefer MESO or PCVX?

Do insiders and institutionals hold more shares of MESO or PCVX?

Does the media favor MESO or PCVX?

Is MESO or PCVX more profitable?

Which has better valuation and earnings, MESO or PCVX?

Summary

How does Mesoblast compare to Immunovant?

Do insiders & institutionals have more ownership in MESO or IMVT?

Which has more volatility & risk, MESO or IMVT?

Do analysts prefer MESO or IMVT?

Does the media refer more to MESO or IMVT?

Which has preferable valuation and earnings, MESO or IMVT?

Is MESO or IMVT more profitable?

Summary

How does Mesoblast compare to Lantheus?

Which has more volatility and risk, MESO or LNTH?

Does the media refer more to MESO or LNTH?

Do analysts prefer MESO or LNTH?

Is MESO or LNTH more profitable?

Which has better valuation & earnings, MESO or LNTH?

Do institutionals & insiders have more ownership in MESO or LNTH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MESO vs. The Competition

Mesoblast Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools